Johnson & Johnson (JNJ) Targets Opportunities around Multiple Myeloma with TECVAYLI

Johnson & Johnson (NYSE:JNJ) is one of Goldman Sachs top healthcare stocks. On March 10, Johnson & Johnson (NYSE:JNJ) announced the submission of a Type II variation application to the European Medicines Agency. The company is seeking approval of TECVAYLI (teclistamab) as a potential treatment for relapsed and refractory multiple Myeloma.

Johnson & Johnson (JNJ) Targets Opportunities around Multiple Myeloma with TECVAYLI

The company hopes to make TECVAYLI available at a time when patients with multiple myeloma continue to relapse. It hopes the drug will be approved as a potential treatment to improve long-term outcomes and change the course of the disease. The submission is supported by data from the Phase 3 MajesTEC-9 trial, which showed that the safety profile of teclistamab monotherapy was clinically manageable.

The submission follows the European Commission approving an indication extension for AKEEGA in combination with androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer. The approval introduces a new precision-based treatment option for patients expected to have the greatest impact in helping change the trajectory of the disease.

“This expanded indication for niraparib and abiraterone acetate reflects our commitment to delivering transformative innovation across the prostate cancer continuum,” said Charles Drake, M.D., Ph.D., FAAP, Vice President, Prostate Cancer and Immunotherapy Disease Area Leader, Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) is a diversified global healthcare company that develops, manufactures, and sells products in two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices).

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.